AbbVie jumps into CD47 game, engineers $2B+ deal with ambitious Chinese player

Gilead’s $4.9 billion bet on Forty Seven evidently triggered a rush among Big Pharma to look for their own drug that targets the CD47 “don’t-eat-me” signal. AbbVie has now jumped on the bandwagon, paying $180 million upfront to license an antibody out of China. I-Mab is keeping China rights to…

Click to view original post